揭示潜力：尿外泌体 mRNAs 作为早期前列腺癌诊断的非侵入性生物标志物。

Unveiling potential: urinary exosomal mRNAs as non-invasive biomarkers for early prostate cancer diagnosis.

机构信息

Department of Urology, The First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Qingxiu, Nanning, Guangxi, 530021, P.R. China.

Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, No.71 Hedi Road, Qingxiu District, Nanning, Guangxi, 530021, P.R. China.

出版信息

BMC Urol. 2024 Aug 1;24(1):163. doi: 10.1186/s12894-024-01540-6.

DOI:10.1186/s12894-024-01540-6

PMID:39090720

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292860/

Abstract

BACKGROUND

This study investigated the use of urinary exosomal mRNA as a potential biomarker for the early detection of prostate cancer (PCa).

METHODS

Next-generation sequencing was utilized to analyze exosomal RNA from 10 individuals with confirmed PCa and 10 individuals without cancer. Subsequent validation through qRT-PCR in a larger sample of 43 PCa patients and 92 healthy controls revealed distinct mRNA signatures associated with PCa.

RESULTS

Notably, mRNAs for RAB5B, WWP1, HIST2H2BF, ZFY, MARK2, PASK, RBM10, and NRSN2 showed promise as diagnostic markers, with AUC values between 0.799 and 0.906 and significance p values. Combining RAB5B and WWP1 in an exoRNA diagnostic model outperformed traditional PSA tests, achieving an AUC of 0.923, 81.4% sensitivity, and 89.1% specificity.

CONCLUSIONS

These findings highlight the potential of urinary exosomal mRNA profiling, particularly focusing on RAB5B and WWP1, as a valuable strategy for improving the early detection of PCa.

摘要

背景

本研究旨在探讨尿外泌体 mRNA 作为前列腺癌（PCa）早期检测潜在生物标志物的应用。

方法

利用下一代测序技术对 10 例确诊为 PCa 的患者和 10 例无癌症患者的尿外泌体 RNA 进行分析。随后，通过 qRT-PCR 在 43 例 PCa 患者和 92 例健康对照者的更大样本中进行验证，揭示了与 PCa 相关的独特 mRNA 特征。

结果

值得注意的是，RAB5B、WWP1、HIST2H2BF、ZFY、MARK2、PASK、RBM10 和 NRSN2 的 mRNA 作为诊断标志物具有潜力，其 AUC 值在 0.799 到 0.906 之间，且具有统计学意义 p 值。在 exoRNA 诊断模型中结合 RAB5B 和 WWP1 的表现优于传统 PSA 测试，AUC 为 0.923，灵敏度为 81.4%，特异性为 89.1%。